Recursion Pharmaceuticals Toekomstige groei
Future criteriumcontroles 2/6
Recursion Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 8.5% en 39.4% per jaar. De winst per aandeel zal naar verwachting groeien met 14.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -105.9% zijn.
Belangrijke informatie
8.5%
Groei van de winst
14.40%
Groei van de winst per aandeel
| Biotechs winstgroei | 24.1% |
| Inkomstengroei | 39.4% |
| Toekomstig rendement op eigen vermogen | -105.93% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 06 May 2026 |
Recente toekomstige groei-updates
Recent updates
News Flash: 9 Analysts Think Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Earnings Are Under Threat
May 04
Recursion Pharmaceuticals! WTH is going on?
Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off!Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Apr 28
RXRX: Later Launch And Higher Costs Will Set Up Cleaner Upside
Analysts have trimmed their price target on Recursion Pharmaceuticals to $6 from $7, citing updated operating expense and share count assumptions, as well as a later expected launch timeline for REC-617. Analyst Commentary Bullish analysts point out that the recent cut to a US$6 price target still reflects confidence in Recursion Pharmaceuticals reaching key development milestones over time, even with updated expense forecasts and a later expected REC-617 launch.Recursion Pharmaceuticals! WTH is going on?
I was very pessimistic about RXRX! I am now extremely optimistic and here’s why!RXRX: Later Launch Assumptions Will Set Up Cleaner Long Term Upside
Analysts recently trimmed their 12 month price target for Recursion Pharmaceuticals to $6 from $7, citing revised operating expense assumptions, a higher share count, and a later expected launch timing for REC-617. Analyst Commentary Recent commentary around Recursion Pharmaceuticals has focused on updated assumptions for operating expenses, a higher share count, and a later expected launch for REC-617.RXRX: Later Launch And Cleaner Model Assumptions Will Support Long Term Upside
Analysts have lowered their price target on Recursion Pharmaceuticals to $6 from $7, citing updated operating expense assumptions, a revised share count, and a later expected launch timing for REC-617. Analyst Commentary While the latest research includes a lower price target, recent commentary still highlights areas where bullish analysts see room for Recursion Pharmaceuticals to execute and create value over time.RXRX: FAP Data And Cautious Outlook Will Support Long Term Thesis
Analysts have trimmed their price target for Recursion Pharmaceuticals to $6 from $7, citing revised estimates, updated operating expense and share count assumptions, and a later expected launch for REC-617. Analyst Commentary Recent commentary points to a more cautious tone on Recursion Pharmaceuticals, with the latest price target reset to reflect updated expense planning, share count expectations, and a later potential launch for REC-617.Recursion Pharmaceuticals! WTH is going on?
As I see what RXRX did in the 4th quarter I now believe they will be the Palantir of biotechnology one day! Najat Khan the new CEO will lead this company out of the hole created by the former CEO into greatness!
RXRX: FAP Trial Success Will Support Future Margin Expansion Potential
Analysts have maintained their $7.00 price target on Recursion Pharmaceuticals, citing broadly consistent long term assumptions and only minor adjustments to the discount rate, profit margin outlook, and future P/E multiple. What's in the News Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an allosteric MEK1/2 inhibitor being studied for familial adenomatous polyposis, with REC-4881 4 mg QD linked to rapid clinical activity in the trial population (Key Developments).RXRX: Positive FAP Trial Data Will Support Stronger Long Term Thesis
Analysts have raised their price target on Recursion Pharmaceuticals to US$11.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of the change. What's in the News Recursion reported positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis.RXRX: Positive FAP Trial Results Will Support Future Margin Expansion
Analysts have modestly adjusted their price target on Recursion Pharmaceuticals, citing updated assumptions around the discount rate, long-term revenue growth, profit margin, and future P/E. Together, these revisions lead to a refined fair value estimate of US$7.00 per share.RXRX: Positive FAP Trial Data Will Support Stronger Long Term Thesis
Analysts have lifted their fair value estimate for Recursion Pharmaceuticals from US$10.00 to US$11.00, citing updated assumptions around revenue growth, profit margin, and future P/E levels as key drivers of the new target. What's in the News Recursion reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (Key Developments).RXRX: Positive TUPELO Data Will Drive Future AI-Enabled Margin Expansion
Analysts have raised their price target on Recursion Pharmaceuticals by approximately 10 percent to around 7.00 dollars per share, citing a modestly higher fair value estimate despite tempered revenue growth assumptions. What's in the News Announced positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, with 75 percent of evaluable patients showing reduced total polyp burden and a 43 percent median reduction after 12 weeks of treatment (Key Developments).RXRX: New CEO Appointment Will Spark Stronger Margins And AI-Driven Momentum
Analysts have modestly raised their price target for Recursion Pharmaceuticals from $6.30 to $6.33 per share. They cite improved forecasted revenue growth and higher profit margins as key drivers behind the update.RXRX: Leadership Change Will Drive Future Opportunity Amid Accelerating Revenue Outlook
Analysts have lowered their price target for Recursion Pharmaceuticals from $6.47 to $6.30, citing adjustments in projected discount rates and profit margins despite stronger expected revenue growth. What's in the News Dr. Najat Khan has been appointed as Chief Executive Officer of Recursion Pharmaceuticals, effective January 1, 2026 (Key Developments).Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Nov 07Recursion: FDA To Replace Animal Testing With AI? - A Small But Necessary Win
Apr 11Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts
Mar 27
REC-617 And REC-994 Trials Will Drive Future AI-Driven Drug Discovery Success
Successful clinical trials and expanded pipeline indicate promising future revenue growth and earnings from potential drug market entries.Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns
Mar 12This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year
Mar 02Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest
Feb 14Recursion: Investors Will Need To Be Patient
Jan 10Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Dec 25Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Dec 09Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
Nov 20Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week
Nov 10Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk
Nov 08Recursion: AI Is Only As Good As The Data
Sep 11Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 220 | -451 | 150 | -240 | 2 |
| 12/31/2027 | 125 | -476 | -227 | -317 | 8 |
| 12/31/2026 | 60 | -410 | -193 | -213 | 4 |
| 3/31/2026 | 66 | -560 | -328 | -321 | N/A |
| 12/31/2025 | 75 | -645 | -380 | -372 | N/A |
| 9/30/2025 | 44 | -716 | -450 | -441 | N/A |
| 6/30/2025 | 65 | -649 | -396 | -383 | N/A |
| 3/31/2025 | 60 | -575 | -401 | -389 | N/A |
| 12/31/2024 | 59 | -464 | -376 | -359 | N/A |
| 9/30/2024 | 65 | -378 | -336 | -318 | N/A |
| 6/30/2024 | 50 | -375 | -346 | -332 | N/A |
| 3/31/2024 | 46 | -354 | -331 | -317 | N/A |
| 12/31/2023 | 45 | -328 | -300 | -288 | N/A |
| 9/30/2023 | 47 | -293 | -277 | -258 | N/A |
| 6/30/2023 | 50 | -260 | -266 | -240 | N/A |
| 3/31/2023 | 47 | -249 | -273 | -234 | N/A |
| 12/31/2022 | 40 | -239 | -121 | -84 | N/A |
| 9/30/2022 | 29 | -247 | -134 | -100 | N/A |
| 6/30/2022 | 18 | -234 | -113 | -78 | N/A |
| 3/31/2022 | 13 | -212 | -75 | -50 | N/A |
| 12/31/2021 | 10 | -186 | -198 | -159 | N/A |
| 9/30/2021 | 10 | -147 | -129 | -89 | N/A |
| 6/30/2021 | 9 | -124 | -106 | -75 | N/A |
| 3/31/2021 | 6 | -99 | -84 | -58 | N/A |
| 12/31/2020 | 4 | -87 | -52 | -45 | N/A |
| 12/31/2019 | 2 | -62 | N/A | -57 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat RXRX de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat RXRX de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat RXRX de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van RXRX ( 39.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 11.3% per jaar).
Hoge groei-inkomsten: De omzet van RXRX ( 39.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat RXRX binnen 3 jaar verliesgevend zal zijn.
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/06 03:48 |
| Aandelenkoers aan het einde van de dag | 2026/05/06 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Recursion Pharmaceuticals, Inc. wordt gevolgd door 13 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Gal Munda | Berenberg |
| Gaurav Goparaju | Berenberg |
| Alec Stranahan | BofA Global Research |